TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06411158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventionist-guided training
Description: Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home pelvic floor exercises guided by the leva® device
Description: Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
Study: NCT04656964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam tosilate group
Description: Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam group
Description: Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
Study: NCT06282757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video placebo communication
Description: The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video nocebo communication
Description: The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
Study: NCT04901715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Technetium99m - Sulfur Colloid (Tc99m-SC)
Description: Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Technetium99m - Sulfur Colloid (Tc99m-SC)
Description: Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Technetium99m - Sulfur Colloid (Tc99m-SC)
Description: Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.
Study: NCT05942040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Palliative Care Information
Description: This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
Study: NCT05059574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Crawling
Description: The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
Study: NCT06084728

Intervention type: DIAGNOSTIC_TEST
Intervention: Color Doppler ultrasonography
Description: in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora

Intervention type: DIAGNOSTIC_TEST
Intervention: Color Doppler ultrasonography
Description: in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
Study: NCT06515509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with or without loading
Description: immediate implant placement with or without loading
Study: NCT06496659

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Segmentectomy
Description: A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
Study: NCT06006468

Intervention type: GENETIC
Intervention: High genetic risk for type 1 diabetes
Description: in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls

Intervention type: GENETIC
Intervention: High gentic risk for Coeliac disease
Description: in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
Study: NCT06113562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFO closure
Description: The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
Study: NCT05816083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Tool
Description: Virtual Reality Tool for At-Risk Trauma-Exposed Young People
Study: NCT06106984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graded motor imagery mobile app
Description: The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
Study: NCT06164756

Intervention type: OTHER
Intervention: Cognitive Behavior Therapy (CBT)
Description: Participants will receive 10 weeks of CBT

Intervention type: OTHER
Intervention: Cognitive Behavior Therapy (CBT)
Description: Participants will receive 10 weeks of CBT

Intervention type: OTHER
Intervention: Treatment As Usual (TAU)
Description: Participants will receive standard of care treatment

Intervention type: OTHER
Intervention: Treatment As Usual (TAU)
Description: Participants will receive standard of care treatment
Study: NCT06384781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Checklist
Description: Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
Study: NCT05431088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osivelotor
Description: Tablets which contain drug substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Osivelotor
Description: Tablets which contain drug substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: Tablets which contain drug substance
Study: NCT06313957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LUCAR-20SP cells
Description: Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Study: NCT05773586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-5918
Description: oral tablets 10mg, 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-5918
Description: oral tablets 10mg, 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT06163807

Intervention type: DRUG
Intervention: Antiasthmatic
Description: real-life

Intervention type: DRUG
Intervention: Antiasthmatic
Description: real-life
Study: NCT05544929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KFA115
Description: Immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KFA115
Description: Immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KFA115
Description: Immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 antibody
Study: NCT05623514

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-vaginal ultrasound
Description: Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
Study: NCT06643962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin
Description: Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
Study: NCT05996068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line
Description: insert arterial line for patients who meet major trauma criteria
Study: NCT05025605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 80 Micrograms
Description: Sublingual film containing 80 Micrograms BXCL501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: Matching Sublingual Placebo film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 120 Micrograms
Description: Sublingual film containing 120 Micrograms BXCL501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 60 Micrograms
Description: Sublingual film containing 60 Micrograms BXCL501 Europe Only
Study: NCT05649540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study: NCT05224726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Applying 5cc of PRP preparation on uterine incision after it has been sutured.
Study: NCT05625841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey product
Description: Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey product
Description: Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
Study: NCT06375863

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QT and QTc interval
Description: measuring of QT and QTc on ECG
Study: NCT05625841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propolis
Description: propolis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT05909436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
Study: NCT06062368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate of Entry
Description: The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate of Entry
Description: The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate of Entry
Description: The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
Study: NCT06146218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative-Based Resilience Training (CBRT)
Description: The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
Study: NCT04788303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School meal, garden, education, and community workshops
Description: School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Garden, education, and community workshops
Description: School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH.
Study: NCT04853667

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview, lasting a maximum of one hour

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview, lasting a maximum of one hour
Study: NCT06247696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Pillows
Description: Pillows containing herbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Pillows
Description: Pillows containing herbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Pillows
Description: Pillows containing herbs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal Pillows
Description: Pillows containing herbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Pillows
Description: Pillows containing herbs
Study: NCT05492383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
Study: NCT04704882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omental patchwork
Description: the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
Study: NCT05545813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
Study: NCT05413967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mills manipulation in addition to myofasical release therapy
Description: Group A will receive Mills manipulation in addition to myofasical release therapy as baselin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nirschl exercises in addition to myofascial release therapy
Description: Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
Study: NCT05798884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
Study: NCT04827121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial iliac compartment block
Description: Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
Study: NCT05798884

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture
Description: Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation.
Study: NCT04990440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Participants will receive bermekimab IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Participants will receive bermekimab IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Participants will receive bermekimab IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo IV.
Study: NCT06529289

Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills.
Study: NCT05293535

Intervention type: OTHER
Intervention: Prognostic study
Description: No intervention... as it is a prognostic study and no intervention done on patients.

Intervention type: OTHER
Intervention: Prognostic study
Description: No intervention... as it is a prognostic study and no intervention done on patients.